Cite

HARVARD Citation

    Pavord, I. et al. (2022). From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases. Allergy. 77 (3), pp. 778-797. [Online]. 
  
Back to record